Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Halpern

Showing results (241-250 of 250) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 250 results.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Haematologica|November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.
Leukemia|October 6, 2019
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasmAnna B Halpern, Nicholas P Howard, Megan Othus, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Blood Advances|February 15, 2023
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasmsJulian Lindsay, Carla S Walti, Anna B Halpern, et al.
Leukemia & Lymphoma|March 20, 2023
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemiaRyan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Scientific Data|June 24, 2020
The Fire and Tree Mortality Database, for empirical modeling of individual tree mortality after fireC Alina Cansler, Sharon M Hood, J Morgan Varner, et al.
Pageof 25

Showing results (241-250 of 250) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 250 results.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Haematologica|November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.
Leukemia|October 6, 2019
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasmAnna B Halpern, Nicholas P Howard, Megan Othus, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Blood Advances|February 15, 2023
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasmsJulian Lindsay, Carla S Walti, Anna B Halpern, et al.
Leukemia & Lymphoma|March 20, 2023
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemiaRyan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Scientific Data|June 24, 2020
The Fire and Tree Mortality Database, for empirical modeling of individual tree mortality after fireC Alina Cansler, Sharon M Hood, J Morgan Varner, et al.
Pageof 25